Evidence map›Paper›PMID 40624535›Full record

Trial reportNutrition journal2025

Impact of supplementing Limosilactobacillus fermentum MN-LF23 on the eradication of Helicobacter pylori with 14-day standard quadruple therapy: a randomized, double-blind, placebo-controlled trial.

Yuyang Zhao, Xiaokang Niu, Yong Zhang, Liang Zhao, Liwei Zhang, Jingjing He, Qi Zhang, Yuejian Mao, Fuqing Wang, Xiaohui Zhao and 1 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrition journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Beyond Antibiotics: Alternative Strategies TargetingExpert reviews in molecular medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuyang ZhaoDepartment of Food Science and Nutritional Engineering, Key Laboratory of Functional Dairy, Co-constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing, China.
Xiaokang NiuDepartment of Nutrition and Health, Key Laboratory of Functional Dairy, Co-Constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing, China.
Yong ZhangDepartment of Nutrition, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Liang ZhaoDepartment of Food Science and Nutritional Engineering, Key Laboratory of Functional Dairy, Co-constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing, China.
Liwei ZhangDepartment of Nutrition and Health, Key Laboratory of Functional Dairy, Co-Constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing, China.
Jingjing HeDepartment of Nutrition and Health, Key Laboratory of Functional Dairy, Co-Constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing, China.
Qi ZhangDepartment of Nutrition and Health, Key Laboratory of Functional Dairy, Co-Constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing, China.
Yuejian MaoMengniu Institute of Nutrition Science, Global R&D Innovation Center, Inner Mongolia Mengniu Dairy (Group) Co., Ltd, Inner Mongolia, China.
Fuqing WangTibet Tianhong Science and Technology Co., Ltd, Xizang, China. fq7963@163.com.
Xiaohui ZhaoMengniu Institute of Nutrition Science, Global R&D Innovation Center, Inner Mongolia Mengniu Dairy (Group) Co., Ltd, Inner Mongolia, China. zhaoxiaohui1@mengniu.cn.
Ran WangDepartment of Nutrition and Health, Key Laboratory of Functional Dairy, Co-Constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing, China. wangran@cau.edu.cn.

Funding

National Key Research and Development Program of China 2022YFF1100100
6 · The paper itself

Abstract

backgroundThe effect of probiotics on Helicobacter pylori (Hp) infection demonstrates considerable heterogeneity. This study aims to elucidate the role of Limosilactobacillus fermentum MN-LF23 (MN-LF23) in Hp-infected populations.

methodsA total of 94 adult patients with confirmed Hp infection were enrolled in this study and randomly allocated to the placebo or MN-LF23 group. Patients initially received either placebo or probiotics along with standard quadruple therapy for 2 weeks, followed by continued administration of either placebo or probiotics for an additional 4 weeks. The eradication of Hp, serum levels of inflammatory factors, and alterations in gastrointestinal symptoms were assessed at weeks 0, 2, and 6, while fecal samples were collected for metagenomic sequencing.

resultsThe results showed no significant difference (P = 1) in the eradication rate between the placebo group (85.11%) and the probiotic group (82.98%). Following treatment, the incidence of constipation, dyspepsia, and Gastrointestinal Symptom Rating Scale (GSRS) scores in the probiotic group were markedly lower (P < 0.05) compared to those observed in the placebo group. Throughout the treatment process, there were no significant differences in TNF-α and IL-1β levels between the two groups. Compared to the placebo group, the probiotic group exhibited a significant increase in beneficial bacteria such as Limosilactobacillus fermentum, Lactiplantibacillus plantarum, Bifidobacterium longum, Coprococcus caltus, and Clostridium butyricum.

conclusionMN-LF23 supplementation did not improve the eradication rate of standard quadruple therapy. However, it significantly reduced the overall GSRS score, improved digestive and constipation symptoms, and promoted the proliferation of beneficial bacteria in the intestine.

Indexed as

Helicobacter InfectionsHelicobacter pyloriLimosilactobacillus fermentumProbioticsAdultAnti-Bacterial AgentsDietary SupplementsDouble-Blind MethodDrug Therapy, CombinationDyspepsiaFecesFemaleGastrointestinal MicrobiomeHumansMaleMiddle AgedAnti-Bacterial AgentsGut microbiotaHelicobacter pyloriLimosilactobacillus fermentumMetagenomic sequencingStandard quadruple therapy

Identifiers

PMID40624535
PMCPMC12235938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.